Status:
COMPLETED
SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Abbott
Conditions:
HIV Infection
Eligibility:
All Genders
Brief Summary
HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavud...
Detailed Description
HIV infected subjects receiving antiretroviral treatment (lopinavir/ritonavir, stavudine, and lamivudine) for greater than 6 years through the Abbott M97-720 protocol with be evaluated for clinical li...
Eligibility Criteria
Inclusion
- HIV infection
- Receiving Kaletra, stavudine, and lamivudine for greater than 6 years (through Abbott M97-720 study)
- Planning to switch from stavudine to tenofovir
Exclusion
- Will continue to receive stavudine
Key Trial Info
Start Date :
November 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00225082
Start Date
November 1 2004
End Date
October 1 2007
Last Update
October 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611